Inventor · disambiguated record
Ashok Bhandari
Also filed as: BHANDARI ASHOK · BHANDARI ASHOK K · BHANDARI ASHOK KUMAR
32 granted patents·42 pending applications·511 citations·filing 1977–2025
97Inventor score
Files withPROTAGONIST THERAPEUTICS INC51JANSSEN BIOTECH INC7AFFYMAX INC4HOLMES CHRISTOPHER P4JANSSEN PHARMACEUTICA NV3
Top patents by PatentIndex Score
74 records- 0198US11111272B2α4α7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·10 cites·14 claims
- 0298US10626146B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Apr 21, 2020·15 cites·22 claims
- 0398US9518091B2A4B7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Dec 13, 2016·34 cites·21 claims
- 0497US10941183B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Mar 9, 2021·13 cites·20 claims
- 0597US10301371B2Cyclic monomer and dimer peptides having integrin antagonist activityPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted May 28, 2019·19 cites·14 claims
- 0697US10196424B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·26 cites·22 claims
- 0797US10059744B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·22 cites·31 claims
- 0897US10035824B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 31, 2018·24 cites·26 claims
- 0997US10023614B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 17, 2018·23 cites·21 claims
- 1097US9809623B2α4β7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Nov 7, 2017·26 cites·14 claims
- 1197US9714270B2a4B7 integrin thioether peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·27 cites·22 claims
- 1297US9624268B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·40 cites·24 claims
- 1396US11472842B2Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·5 cites·11 claims
- 1495US11041000B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·13 cites·26 claims
- 1595US10729676B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·10 cites·18 claims
- 1695US9273093B2α4β7 peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2013·Granted Mar 1, 2016·31 cites·8 claims
- 1794US11845808B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Dec 19, 2023·3 cites·30 claims
- 1894US10278957B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·16 cites·19 claims
- 1993US10787490B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·18 cites·18 claims
- 2091US10407468B2Methods for synthesizing α4β7 peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·13 cites·24 claims
- 2188US11840581B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Dec 12, 2023·1 cites·17 claims
- 2288US2024199700A1Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2386US11753443B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·3 cites·10 claims
- 2486US2024209026A1A4b7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2585US11939361B2Compositions of peptide inhibitors of Interleukin-23 receptorJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Mar 26, 2024·2 cites·16 claims
- 2684US5536516AHydroxycitric acid concentrate and food products prepared therefromRENAISSANCE HERBS INC·Filed 1994·Granted Jul 16, 1996·53 cites·10 claims
- 2783US5656314AHydroxycitric acid concentrate and food products prepared therefromFiled 1996·Granted Aug 12, 1997·55 cites·17 claims
- 2882US12018057B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Jun 25, 2024·1 cites·10 claims
- 2979US8106154B2Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromoleculesHOLMES CHRISTOPHER P·Filed 2008·Granted Jan 31, 2012·4 cites·4 claims
- 3078US12234300B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 3176US11884748B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·21 claims
- 3275US2022162261A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3372US2024150405A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 3472US2024383954A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 3572US2020239523A1NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3671US2024132558A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3770US2024066131A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3870US2024018189A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3968US2023295259A1Conjugated Hepcidin MimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4067US12478617B2Lipidated peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2023·Granted Nov 25, 2025·0 cites·40 claims
- 4164US2025304624A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4264US2025361280A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4364US2024254180A1Compositions of peptide inhibitors of interleukin-23 receptorJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 4463US2024279281A1Peptide Inhibitors of Interleukin-23 ReceptorJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 4562US2025170216A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4661US2018148477A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4761US2022041658A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4860US2024209053A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4960US2024226225A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5058US2024352073A1Bicyclic peptide inhibitors of interleukin-23 receptorJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ashok Bhandari files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →